ABUS

Arbutus Biopharma Corporationdistress 0/10 · well-funded / low risk

$4.33+0%today-17% from 52w high

arbutusbio.com19 employeesFounded 2005Warminster, PABiotechnology

Infectious Disease 2

Lead: Chronic Hepatitis b · est. market ~$10B (approx, global)

Revenue

$179M

Liquidity

$97M

Runway

2.8 yrs

Shares 1y

+3%

Price & events

+4.2% over 6M

CatalystRating changeDilutionFinancingdashed = today

+0.1%

-8.5%

-2.6%

+2.0%

+6.8%

+34.2%

+13.2%

+57.1%

+19.1%

All

Overview

Market Cap: $856.33M
Enterprise Value: $832.62M
Volume: 257.35K
52 Week Range: $3.13 – $5.22
Total Shares: 197.54M
Float Shares: 122.89M
Short %: 12.89%
% Held by Insiders: 20.46%
% Held by Institutions: 71.92%
RVOL: 0.10x
Beta: 0.62

Pipeline stages · 2 programs

AB-729, Peg-IFNα-2a

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

AB-101, Nucleos(t)ide Analogue

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 2 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2025-12-04	Phase 1	AB-101, Nucleos(t)ide Analogue	Chronic Hepatitis b	128	completed
2025-03-13	Phase 2	AB-729, Peg-IFNα-2a	Chronic Hepatitis b	43	completed

Catalyst news & presentations · 10

2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
2026-03-03partnershipSettlement agreement with Moderna to resolve LNP patent litigation, including $950M noncontingent payment and royalty-free license for mRNA vaccines.SEC 8-K
2026-01-15withdrawalLNP technology · EPO Board of Appeal revoked patent EP2279254SEC 8-K
November 7-11, 2025conferencedata presentationsecondaryAB-101 · One abstract accepted for poster presentation (Poster of Distinction) at AASLD The Liver Meeting 2025.SEC 8-K
November 7-11, 2025conferencedata presentationsecondaryimdusiran · Three abstracts accepted for poster presentation at AASLD The Liver Meeting 2025.SEC 8-K
2025-09-09partnershipClaim construction ruling in patent infringement lawsuit against Pfizer/BioNTechSEC 8-K
2025-06-20withdrawalimdusiran · Termination of license agreement with Qilu; reacquired imdusiran rights in Greater China and Taiwan.SEC 8-K
May 7 - 10, 2025conferencedata presentationsecondaryPoster presentation at EASL Congress 2025SEC 8-K
May 7, 2025conferencedata presentationsecondaryAB-101 · Poster presentation at EASL Congress 2025SEC 8-K
May 7, 2025conferencedata presentationsecondaryimdusiran · Poster presentation at EASL Congress 2025SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 197,537,710 · 0 offerings/1y · 0 PIPEs

2026-03-038-Kmaterial_agreement
2025-03-038-Kmaterial_agreement
2024-12-05EFFECTshelf_effective
2024-11-14SC 13G/Astrategic_stake
2024-11-06S-3shelf_registration

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

strong buy · target $5 (+19% upside) · 2 analysts

2025-11-14Chardan CapitalBuy
2025-08-11Chardan CapitalBuy
2025-03-28Chardan CapitalBuy
2025-01-21HC Wainwright & Co.Buy
2024-11-20Chardan CapitalBuy
2024-11-18HC Wainwright & Co.Buy

Competitors — Chronic Hepatitis b

GSKGSK plc$217.0B · D1
GILDGILEAD SCIENCES, INC.$159.5B · D2
IONSIONIS PHARMACEUTICALS INC$9.2B · D2
VIRVir Biotechnology, Inc.$1.6B · D4
GYREGYRE THERAPEUTICS, INC.$571M · D1
ASMBASSEMBLY BIOSCIENCES, INC.$402M · D8
ALGSAligos Therapeutics, Inc.$217M · D3
DTILPRECISION BIOSCIENCES INC$185M · D6
BRNSBarinthus Biotherapeutics plc.$25M · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.